Claims
- 1. A method for the stimulation of bactericidal permeability increasing protein (BPI) in a subject's tissue, comprising the step of administering a therapeutically effective amount of lipoxin or a lipoxin analog, such that the subject's tissues express increased levels of BPI to treat infection.
- 2. The method of claim 1, wherein the lipoxin analog has the formula:
- 3. The method of claim 1, wherein the lipoxin analog has the formula:
- 4. The method of claim 1, wherein the lipoxin analog has the formula:
- 5. A method for the stimulation of bactericidal permeability increasing protein (BPI) in a mucosal cell, comprising the step of administering a therapeutically effective amount of lipoxin or a lipoxin analog, such that the mucosal cell expresses increased levels of BPI to treat infection.
- 6. The method of claim 5, wherein the mucosal cells are epithelial cells.
- 7. The method of claim 5, wherein the mucosal cells are oral epithelial cells.
- 8. The method of claim 5, wherein the epithelial cells are intestinal cells.
- 9. The method of claim 5, wherein the lipoxin analog has the formula:
- 10. The method of claim 5, wherein the lipoxin analog has the formula:
- 11. The method of claim 5, wherein the lipoxin analog has the formula:
- 12. A method for inhibition or prevention of infection by bacteria in a subject, comprising the step of administering a therapeutically effective amount of a-lipoxin or lipoxin analog to the subject suitable to cause mucosal cells in the subject to express increased levels of BPI, such that infection by bacteria in the subject is prevented or inhibited.
- 13. The method of claim 12, wherein the mucosal cells are epithelial cells.
- 14. The method of claim 12, wherein the mucosal cells are oral epithelial cells.
- 15. The method of claim 12, wherein the epithelial cells are intestinal cells.
- 16. The method of claim 12, wherein the lipoxin analog has the formula:
- 17. The method of claim 12, wherein the lipoxin analog has the formula:
- 18. The method of claim 12, wherein the lipoxin analog has the formula:
- 19. A method for inhibition or prevention of invasion by bacteria in a subject, comprising the step of administering a therapeutically effective amount of a lipoxin or lipoxin analog to the subject suitable to cause mucosal cells in the subject to express increased levels of BPI, such that invasion by bacteria in the subject is prevented or inhibited.
- 20. The method of claim 19, wherein the mucosal cells are epithelial cells.
- 21. The method of claim 19, wherein the mucosal cells are oral epithelial cells.
- 22. The method of claim 19, wherein the epithelial cells are intestinal cells.
- 23. The method of claim 19, wherein the lipoxin analog has the formula:
- 24. The method of claim 19, wherein the lipoxin analog has the formula:
- 25. The method of claim 19, wherein the lipoxin analog has the formula:
CROSS-REFERENCE TO RELATED APPLICATION(S)
[0001] The present application claims priority to U.S. provisional patent application No. 60/342,138, filed Dec. 18, 2001.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
[0002] The work leading to this invention was supported in part by National Institutes of Health (NIH) grants RO-1 DK50189 and PO-1 DE13499. The U.S. Government therefore may have certain rights in the invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60342138 |
Dec 2001 |
US |